174 related articles for article (PubMed ID: 22406361)
1. The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma.
Hooper JE; Morgan TK; Grompe M; Sheppard BC; Troxell ML; Corless CL; Streeter PR
Hum Pathol; 2012 Oct; 43(10):1583-9. PubMed ID: 22406361
[TBL] [Abstract][Full Text] [Related]
2. Human pancreatic cancer fusion 2 (HPC2) 1-B3: a novel monoclonal antibody to screen for pancreatic ductal dysplasia.
Morgan TK; Hardiman K; Corless CL; White SL; Bonnah R; Van de Vrugt H; Sheppard BC; Grompe M; Cosar EF; Streeter PR
Cancer Cytopathol; 2013 Jan; 121(1):37-46. PubMed ID: 22811080
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma.
Lok T; Chen L; Lin F; Wang HL
Hum Pathol; 2014 Feb; 45(2):394-400. PubMed ID: 24439226
[TBL] [Abstract][Full Text] [Related]
5. Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels.
Kälsch J; Padden J; Bertram S; Pott LL; Reis H; Westerwick D; Schaefer CM; Sowa JP; Möllmann D; Fingas C; Dechȇne A; Sitek B; Eisenacher M; Canbay A; Ahrens M; Baba HA
Virchows Arch; 2017 May; 470(5):537-543. PubMed ID: 28357490
[TBL] [Abstract][Full Text] [Related]
6. N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas.
Mosnier JF; Kandel C; Cazals-Hatem D; Bou-Hanna C; Gournay J; Jarry A; Laboisse CL
Mod Pathol; 2009 Feb; 22(2):182-90. PubMed ID: 18622386
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells.
Padden J; Ahrens M; Kälsch J; Bertram S; Megger DA; Bracht T; Eisenacher M; Kocabayoglu P; Meyer HE; Sipos B; Baba HA; Sitek B
Mol Cell Proteomics; 2016 Mar; 15(3):1072-82. PubMed ID: 26644413
[TBL] [Abstract][Full Text] [Related]
8. Albumin expression distinguishes bile duct adenomas from metastatic adenocarcinoma.
Moy AP; Arora K; Deshpande V
Histopathology; 2016 Sep; 69(3):423-30. PubMed ID: 26841202
[TBL] [Abstract][Full Text] [Related]
9. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
10. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.
Riener MO; Vogetseder A; Pestalozzi BC; Clavien PA; Probst-Hensch N; Kristiansen G; Jochum W
Hum Pathol; 2010 Nov; 41(11):1558-65. PubMed ID: 20621328
[TBL] [Abstract][Full Text] [Related]
11. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
[TBL] [Abstract][Full Text] [Related]
12. Review and Application of Integrin Alpha v Beta 6 in the Diagnosis and Treatment of Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma.
Lian Y; Zeng S; Wen S; Zhao X; Fang C; Zeng N
Technol Cancer Res Treat; 2023; 22():15330338231189399. PubMed ID: 37525872
[TBL] [Abstract][Full Text] [Related]
13. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.
Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM
Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional analysis of extrahepatic cholangiocarcinoma and tumor budding.
Yoshizawa T; Hong SM; Jung D; Noë M; Kiemen A; Wu PH; Wirtz D; Hruban RH; Wood LD; Oshima K
J Pathol; 2020 Aug; 251(4):400-410. PubMed ID: 32476131
[TBL] [Abstract][Full Text] [Related]
15. C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis.
Yeh YC; Lei HJ; Chen MH; Ho HL; Chiu LY; Li CP; Wang YC
Am J Surg Pathol; 2017 Dec; 41(12):1630-1641. PubMed ID: 28945626
[TBL] [Abstract][Full Text] [Related]
16. CDH17+/CDX2+ Can be Helpful in Providing Support for Small Intestinal Origin Versus Pancreatic or Biliary Origin.
Ma H; Xiao W; Wang M; Shi X
Appl Immunohistochem Mol Morphol; 2021 Aug; 29(7):541-545. PubMed ID: 33958523
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratin profile relates to histological subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of liver.
Shimonishi T; Miyazaki K; Nakanuma Y
Histopathology; 2000 Jul; 37(1):55-63. PubMed ID: 10931219
[TBL] [Abstract][Full Text] [Related]
18. Multiparameter digital image analysis of biliary, ampullary, and pancreatic adenocarcinomas.
Yeaton P; Kiss R; DePrez C; Salmon I; Pasteels JL; Jones RS; Frierson HF
Mod Pathol; 1995 Oct; 8(8):843-7. PubMed ID: 8552573
[TBL] [Abstract][Full Text] [Related]
19. The Das-1 immunostain is useful for discriminating metastatic colon adenocarcinoma from cholangiocarcinoma and hepatocellular carcinoma.
Zimmerman RL; Das KM; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(6):1369-72. PubMed ID: 12375050
[TBL] [Abstract][Full Text] [Related]
20. FOXF1 as an Immunohistochemical Marker of Hilar Cholangiocarcinoma or Metastatic Pancreatic Ductal Adenocarcinoma. Single Institution Experience.
Hrudka J; Prouzová Z; Mydlíková K; Jedličková K; Holešta M; Whitley A; Havlůj L
Pathol Oncol Res; 2021; 27():1609756. PubMed ID: 34257615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
